Proton Pump Inhibitors (PPI) Market To Reach $5.31 Billion by 2035

Proton Pump Inhibitors (PPI) market was valued at $3.20 billion in 2025 and is projected to reach $5.31 billion by 2035, growing at a CAGR of 5.2% during the forecast period (2026–2035). The increasing prevalence of gastrointestinal disorders, rising aging population, and growing consumption of processed food products are major macro drivers supporting market growth globally. According to the World Health Organization (WHO), digestive diseases continue to contribute significantly to the global disease burden, with gastroesophageal reflux disease (GERD) and peptic ulcer disorders witnessing increasing incidence across developed and emerging economies. Growing awareness regarding acid-related gastrointestinal complications and increasing availability of over-the-counter (OTC) medications are accelerating the adoption of proton pump inhibitors worldwide.

Browse the full report description of “Proton Pump Inhibitors (PPI) Market Size, Share & Trends Analysis Report, By Drug Type (Omeprazole, Esomeprazole, Pantoprazole, Lansoprazole, Dexlansoprazole, Rabeprazole), By Formulation (Tablets, Capsules, Injectable PPIs, Oral Suspensions/Granules), By End User (Hospitals, Specialty Gastroenterology Clinics, Ambulatory Surgical Centers, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/proton-pump-inhibitors-ppi-market

The increasing burden of gastrointestinal disorders is significantly supporting market expansion.

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 20% of the US population experiences symptoms of GERD regularly. In addition, the U.S. Food and Drug Administration (FDA) has approved several proton pump inhibitor formulations for the treatment of acid reflux, peptic ulcer disease, erosive esophagitis, and Helicobacter pylori infection management. Rising healthcare expenditure, increasing accessibility to generic PPIs, and growing hospital admissions for gastrointestinal complications are further boosting market demand. Hospitals and specialty gastroenterology clinics continue to dominate the end-user segment owing to increasing patient visits related to chronic digestive disorders and long-term acid suppression therapies.

Growing Demand for Advanced Oral Formulations and Injectable PPIs Supporting Market Growth

The formulation segment is witnessing strong growth due to increasing demand for convenient oral dosage forms and advanced injectable proton pump inhibitor therapies for critical care settings. Tablets remain the dominant segment owing to their high prescription volume, affordability, and widespread OTC availability. However, injectable PPIs are projected to witness rapid growth due to increasing hospitalization rates for gastrointestinal bleeding, ulcers, and severe acid reflux disorders. The growing preference for improved patient compliance and rapid symptom management is encouraging manufacturers to develop enhanced-release formulations and combination therapies. Homecare settings are also emerging as a fast-growing end-user segment due to increasing self-medication trends and expanding availability of OTC proton pump inhibitors globally.

Key Leaders Transforming the Proton Pump Inhibitors (PPI) Market

The key players in the proton pump inhibitors (PPI) market include AstraZeneca, Takeda Pharmaceutical Company, Pfizer, Eisai Co., Ltd., Sanofi, among others. These companies are focusing on product expansion, partnerships, acquisitions, and geographical expansion strategies to strengthen their market presence.

• In March 2026, Takeda Pharmaceutical Company announced the next phase of its global transformation strategy to strengthen competitiveness and accelerate future growth. The company stated that the initiative is expected to generate annualized gross savings of over JPY 200 billion by FY2028 through operational streamlining, process simplification, and advanced technology integration to support upcoming product launches and long-term pipeline expansion.
• In January 2026, AstraZeneca announced plans to invest $15 billion in China through 2030 to expand medicines manufacturing, research, and development capabilities. The investment will strengthen the company’s cell therapy and radioconjugate capabilities, expand operations across Beijing, Shanghai, Qingdao, Taizhou, and Wuxi, and support the development of next-generation therapies for oncology, hematology, and autoimmune diseases.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drug Type
• Formulation
• End User
• Competitive Landscape – AstraZeneca, Takeda Pharmaceutical Company, Pfizer, Eisai Co., Ltd., Sanofi, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Proton Pump Inhibitors (PPI) Market Segmentation

By Drug Type

• Omeprazole
• Esomeprazole
• Pantoprazole
• Lansoprazole
• Dexlansoprazole
• Rabeprazole

By Formulation

• Tablets
• Capsules
• Injectable PPIs
• Oral Suspensions/Granules

By End User

• Hospitals
• Specialty Gastroenterology Clinics
• Ambulatory Surgical Centers
• Homecare Settings

 Global Proton Pump Inhibitors (PPI) Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/industry-reports/proton-pump-inhibitors-ppi-market